- Zealand Pharma A/S (NASDAQ:ZEAL) has dosed first subject in a Phase 1 trial to evaluate the safety and tolerability of ZP7570 as a potential treatment of short bowel syndrome (SBS).
- The study is a randomized, placebo-controlled trial in 64 healthy subjects, randomized to ZP7570 or placebo within eight cohorts.
- ZP7570, a long-acting, dual GLP-1/GLP-2 peptide therapeutic, is designed to further improve management of SBS.